A joint study by University of East Anglia and University of Glasgow performs a meta-analysis of 167 experiments across eight vertebrate species, showing rapamycin reliably matches the life-extension benefits of intermittent fasting without requiring dietary restriction, highlighting its promise for further aging therapeutics.
Key points
- Meta-analysis of 167 experiments across eight vertebrate species reveals rapamycin matches lifespan gains of intermittent fasting.
- Rapamycin extends life in fish, rodents, and primates regardless of sex or feeding protocol, whereas metformin lacks consistent benefits.
- Study employs systematic review methodology to benchmark rapamycin against calorie restriction, supporting its potential for human aging trials.
Why it matters: The study underscores drug repurposing potential for practical, less restrictive longevity interventions with significant implications for aging therapeutics.
Q&A
- What is rapamycin?
- How does dietary restriction extend lifespan?
- What is a meta-analysis in this context?
- Why did metformin show no lifespan benefit?